Table 1. Prevalence of CTC: comparison between CellSearch and EPISPOT assays.
VariableCTC CellSearch, n (%)CTC EPISPOT, n (%)
≥1 (n = 142)≥5 (n = 97)≥10 (n = 83)≥100 (n = 33)≥1 (n = 115)≥5 (n = 88)≥10 (n = 68)≥100 (n = 19)
Age class
    <60 years80 (56.3%)53 (54.6%)48 (57.8%)22 (66.7%)55 (47.8%)42 (47.7%)37 (54.4%)13 (68.4%)
    ≥60 years62 (43.7%)44 (45.4%)35 (42.2%)11 (33.3%)60 (52.2%)46 (52.3%)31 (45.6%)6 (31.6%)
Histology
    Ductal112 (78.9%)74 (76.3%)62 (74.7%)24 (72.7%)87 (75.7%)69 (78.4%)54 (79.4%)13 (68.4%)
    Lobular15 (10.6%)11 (11.3%)9 (10.8%)6 (18.2%)13 (11.3%)9 (10.2%)6 (8.8%)3 (15.8%)
    Others15 (10.6%)12 (12.4%)12 (14.5%)3 (9.1%)15 (13%)10 (11.4%)8 (11.8%)3 (15.8%)
Estrogen receptor status
    Negative36 (25.4%)25 (25.8%)24 (28.9%)11 (33.3%)29 (25.2%)24 (27.3%)16 (23.5%)6 (31.6%)
    Positive106 (74.6%)72 (74.2%)59 (71.1%)22 (66.7%)86 (74.8%)64 (72.7%)52 (76.5%)13 (68.4%)
Progesterone receptor status
    Negative52 (36.6%)36 (37.1%)33 (39.8%)14 (42.4%)41 (35.7%)36 (40.9%)28 (41.2%)8 (42.1%)
    Positive90 (63.4%)61 (62.9%)50 (60.2%)19 (57.6%)74 (64.3%)52 (59.1%)40 (58.8%)11 (57.9%)
HER2 status
    Missing17 (12%)10 (10.3%)10 (12%)2 (6.1%)15 (13%)13 (14.8%)8 (11.8%)4 (21.1%)
    Negative88 (62%)61 (62.9%)49 (59%)22 (66.7%)65 (56.5%)47 (53.4%)38 (55.9%)10 (52.6%)
    Positive37 (26.1%)26 (26.8%)24 (28.9%)9 (27.3%)35 (30.4%)28 (31.8%)22 (32.4%)5 (26.3%)
Metastatic sites
    Bone19 (13.4%)11 (11.3%)9 (10.8%)2 (6.1%)15 (13%)12 (13.6%)10 (14.7%)3 (15.8%)
    Visceral50 (35.2%)32 (33%)29 (34.9%)9 (27.3%)45 (39.1%)33 (37.5%)25 (36.8%)4 (21.1%)
    Multiple73 (51.4%)54 (55.7%)45 (54.2%)22 (66.7%)55 (47.8%)43 (48.9%)33 (48.5%)12 (63.2%)
Number of metastatic sites
    One site41 (28.9%)27 (27.8%)24 (28.9%)8 (24.2%)36 (31.3%)27 (30.7%)20 (29.4%)4 (21.1%)
    Multiple sites101 (71.1%)70 (72.2%)59/83 (71.1%)25 (75.8%)79 (68.7%)61 (69.3%)48 (70.6%)15 (78.9%)
Disease-free interval
    ≤12 months36 (25.4%)28 (28.9%)22/83 (26.5%)13 (39.4%)25 (21.7%)20 (22.7%)17 (25%)5 (26.3%)
    >12 months106 (74.6%)69 (71.1%)61/83 (73.5%)20 (60.6%)90 (78.3%)68 (77.3%)51 (75%)14 (73.7%)
Therapeutic setting
    First line58 (40.8%)43 (44.3%)36/83 (43.4%)17 (51.5%)45 (39.1%)34 (38.6%)27 (39.7%)9 (47.4%)
    Second line39 (27.5%)22 (22.7%)18/83 (21.7%)5 (15.2%)31 (27%)18 (20.5%)14 (20.6%)4 (21.1%)
    Third line or more45 (31.7%)32 (33%)29/83 (34.9%)11 (33.3%)39 (33.9%)36 (40.9%)27 (39.7%)6 (31.6%)